# ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine

> **NCT05752201** · PHASE2,PHASE3 · COMPLETED · sponsor: **Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno** · enrollment: 2014 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** Gamma Variant RBD-based ARVAC-CG vaccine
- **BIOLOGICAL:** Omicron Variant RBD-based ARVAC-CG vaccine
- **BIOLOGICAL:** Bivalent RBD-based ARVAC-CG vaccine
- **OTHER:** Placebo (Alum)

## Key facts

- **NCT ID:** NCT05752201
- **Lead sponsor:** Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-06
- **Primary completion:** 2023-08-22
- **Final completion:** 2023-12-07
- **Target enrollment:** 2014 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05752201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05752201, "ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05752201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*